Compare GSK plc (GSK) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares Core MSCI EAFE ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 2.1× GSK plc's market cap, and GSK plc pays a 3.9% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| GSK | IEFA | |
|---|---|---|
Market Cap | $91.88B | $189.19B |
Volume | 7,730,529 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $101.41 |
52-Week Low | $43.24 | $85.06 |
Typical Hold Time | 93 Days | 40 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
IEFA, the iShares Core MSCI EAFE ETF, trades at $95.87, down 0.34% on the day, with a bearish technical signal driven by moving averages and oscillators. The fund provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower costs relative to some peers, though it has underperformed others on a total return basis over the past year.
The outlook for IEFA is mixed, offering diversification benefits and income through dividends but facing headwinds from weaker relative performance and bearish technical momentum. Key risks include concentration in developed markets, which may lag during global growth shifts, and expense ratio competition. Analyst sentiment is cautious due to recent underperformance versus broader global funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
